Pcn163 - Cost-Effectiveness of Add-On Pertuzumab Combined With Trastuzumab and Docetaxel Versus Placebo as Treatment of Her-2 Positive Metastatic Breast Cancer in Czech Republic
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.246
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV